US a multi-asset longevity biotech Cambrian Biopharma yesterday unveiled its latest pipeline company, as Isterian Biotech. emerged from stealth, headquartered in New York.
This pre-clinical start-up is working towards the development of first-in-class small molecule inhibitors of transglutaminase 2 (TG2), one of the major crosslinking enzymes in the human body, which becomes more active during aging resulting in fibrotic diseases.
With age a chronic increase of crosslinked proteins occurs in the extracellular matrix (ECM), which is a large network of proteins and other molecules that surround, support, and give structure to the cells and tissues in the body. These crosslinked proteins are difficult for the body to degrade and over time make organs stiff and dysfunctional, ultimately resulting in fibrosis. Reversing the accumulation of these pathological crosslinks will greatly contribute to reducing fibrosis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze